



SAFETY DATA SHEET

Revision date: 01-Mar-2016

Version: 5.1

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Docetaxel Injection

Trade Name: Docetaxel; Pfizer Docetaxel

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Antineoplastic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
Poisons Information Centre: 13 1126

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 2

Reproductive Toxicity: Category 1B

Effects on or via lactation

Flammable liquids- Category 2

Label Elements

Signal Word: Danger

Hazard Statements:
H225 - Highly flammable liquid and vapor
H319 - Causes serious eye irritation
H341 - Suspected of causing genetic defects
H360D - May damage the unborn child
H362 - May cause harm to breast-fed children

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 2 of 11
Version: 5.1

Precautionary Statements:

- P202 - Do not handle until all safety precautions have been read and understood
- P210 - Keep away from heat/sparks/open flames/hot surfaces. - No smoking
- P233 - Keep container tightly closed
- P240 - Ground/Bond container and receiving equipment
- P241 - Use explosion-proof electrical/ventilating/lighting/equipment
- P242 - Use only non-sparking tools
- P243 - Take precautionary measures against static discharge
- P280 - Wear protective gloves/protective clothing/eye protection/face protection
- P303 + P361 + P353 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower
- P308 + P313 - IF exposed or concerned: Get medical attention/advice
- P403 + P235 - Store in a well-ventilated place. Keep cool
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations
- P370 + P378 - In case of fire: Use CO₂, extinguishing powder, foam, or water for extinction



Other Hazards Note:

No data available
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Ethyl alcohol (ethanol)	64-17-5	200-578-6	Flam. Liq. 2 (H225)	<40
Citric acid, anhydrous	77-92-9	201-069-1	Not Listed	**
Docetaxel anhydrous	114977-28-5	Not Listed	Repr. 1B (H360D) Muta. 2 (H341) Eye Irrit. 2A (H319) Lact. (H362)	1
Propylene glycol	57-55-6	200-338-0	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*
Edetate disodium	139-33-3	205-358-3	Not Listed	*

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 3 of 11
Version: 5.1

Additional Information: * Proprietary
** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. For information on potential delayed effects, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 4 of 11
Version: 5.1

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Flammable liquid and vapor- keep away from ignition sources and clean up spills promptly. Eliminate possible ignition sources (e.g., heat, sparks, flame, impact, friction, electricity), and follow appropriate grounding and bonding procedures. Avoid contact with eyes, skin, and clothing. Use appropriate personal protective equipment. Wash thoroughly after handling. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Specific end use(s):	Pharmaceutical product used as Antineoplastic

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Ethyl alcohol (ethanol)

ACGIH Threshold Limit Value (STEL)	1000 ppm
Australia TWA	1000 ppm
	1880 mg/m ³
Austria OEL - MAKs	1000 ppm
	1900 mg/m ³
Belgium OEL - TWA	1000 ppm
	1907 mg/m ³
Bulgaria OEL - TWA	1000.0 mg/m ³
Czech Republic OEL - TWA	1000 mg/m ³
Denmark OEL - TWA	1000 ppm
	1900 mg/m ³
Estonia OEL - TWA	500 ppm
	1000 mg/m ³
Finland OEL - TWA	1000 ppm
	1900 mg/m ³
France OEL - TWA	1000 ppm
	1900 mg/m ³
Germany - TRGS 900 - TWAs	500 ppm
	960 mg/m ³
Germany (DFG) - MAK	500 ppm
	960 mg/m ³
Greece OEL - TWA	1000 ppm
	1900 mg/m ³
Hungary OEL - TWA	1900 mg/m ³
Latvia OEL - TWA	1000 mg/m ³
Lithuania OEL - TWA	500 ppm
	1000 mg/m ³
Netherlands OEL - TWA	260 mg/m ³

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 5 of 11
Version: 5.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELs - TWAs:	1000 ppm 1900 mg/m ³
Poland OEL - TWA	1900 mg/m ³
Portugal OEL - TWA	1000 ppm
Romania OEL - TWA	1000 ppm 1900 mg/m ³
Russia OEL - TWA	1000 mg/m ³
Slovakia OEL - TWA	500 ppm 960 mg/m ³
Slovenia OEL - TWA	1000 ppm 1900 mg/m ³
Sweden OEL - TWAs	500 ppm 1000 mg/m ³
Switzerland OEL -TWAs	500 ppm 960 mg/m ³
Vietnam OEL - TWAs	1000 mg/m ³
Propylene glycol	
Australia TWA	150 ppm 474 mg/m ³ 10 mg/m ³
Ireland OEL - TWAs	150 ppm 470 mg/m ³ 10 mg/m ³
Latvia OEL - TWA	7 mg/m ³
Lithuania OEL - TWA	7 mg/m ³
Docetaxel anhydrous	
Pfizer Occupational Exposure Band (OEB):	OEB 4 (control exposure to the range of 1ug/m ³ to <10ug/m ³)
Exposure Controls	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Clear, colorless to pale yellow
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 6 of 11
Version: 5.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Water Solubility: No data available
pH: 4-7
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Docetaxel anhydrous
No data available
Citric acid, anhydrous
No data available
Polysorbate 80
No data available
Propylene glycol
No data available
Ethyl alcohol (ethanol)
No data available
Edetate disodium
No data available
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): 24
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May cause eye irritation (based on components) .
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on central nervous system, gastrointestinal system, blood and blood forming organs, and testes.
Known Clinical Effects: Common adverse effects include blood cell changes, nervous system/brain toxicity (neurotoxicity). Serious allergic reactions, including anaphylaxis, have been reported.

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 7 of 11
Version: 5.1

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Docetaxel anhydrous

Rat Oral LD50 > 2000 mg/kg
Mouse IV LD50 138mg/kg

Citric acid, anhydrous

Rat Oral LD50 3000 mg/kg

Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg
Mouse Oral LD 50 25 g/kg

Propylene glycol

Rat Oral LD 50 22,000 mg/kg
Mouse Oral LD 50 24,900mg/kg
Rabbit Dermal LD 50 20,800mg/kg

Ethyl alcohol (ethanol)

Mouse Oral LD50 3450 mg/kg
Rat Oral LD50 7060mg/kg
Rat Inhalation LC50 10h 20,000ppm

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Docetaxel anhydrous

Eye Irritation Rabbit Irritant
Skin Irritation Rabbit Non-irritating
Skin Sensitization Negative

Citric acid, anhydrous

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Mild

Propylene glycol

Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Ethyl alcohol (ethanol)

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 8 of 11
Version: 5.1

11. TOXICOLOGICAL INFORMATION

Docetaxel anhydrous

28-31 Day(s)	Rat	Intravenous	mg/m2/day	NOEL	Blood forming organs, Male reproductive system
6 Month(s)	Rat	Intravenous	0.2 mg/kg/day	NOEL	Blood forming organs, Male reproductive system
6 Month(s)	Dog	Intravenous	0.375 mg/kg/day	LOAEL	Male reproductive system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Docetaxel anhydrous

Reproductive & Fertility	Rat	Intravenous	mg/kg/day	LOAEL	Paternal toxicity
Embryo / Fetal Development	Rat	Intravenous	0.3 mg/kg/day	LOAEL	Maternal Toxicity, Embryotoxicity, Fetotoxicity, Not Teratogenic
Embryo / Fetal Development	Rabbit	Intravenous	0.03 mg/kg/day	LOAEL	Embryotoxicity, Fetotoxicity, Maternal Toxicity, Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Docetaxel anhydrous

<i>In Vitro</i> Bacterial Mutagenicity (Ames)	<i>Salmonella</i> , <i>E. coli</i>	Negative
<i>In Vivo</i> Micronucleus	Mouse	Positive
<i>In Vitro</i> Chromosome Aberration	Chinese Hamster Ovary (CHO) cells	Positive

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Ethyl alcohol (ethanol)

IARC: Group 1 (Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Docetaxel anhydrous

<i>Daphnia magna</i> (Water Flea)	LC50	48 Hours	> 3.3 mg/L
-----------------------------------	------	----------	------------

Ethyl alcohol (ethanol)

<i>Oncorhynchus mykiss</i> (Rainbow Trout)	LC50/96h	12,900-15,300 mg/L
--	----------	--------------------

Aquatic Toxicity Comments:

A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability:

No data available

Bio-accumulative Potential:

No data available

Mobility in Soil:

No data available

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 9 of 11
Version: 5.1

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number:	UN 1170
UN proper shipping name:	Ethanol solution
Transport hazard class(es):	3
Packing group:	III
Flash Point (°C):	24
Flash Point (°C):	24

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Ethyl alcohol (ethanol)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 4/29/11 in alcoholic beverages developmental toxicity initial date 10/1/87 in alcoholic beverages
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-578-6

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 10 of 11
Version: 5.1

15. REGULATORY INFORMATION

Citric acid, anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-069-1

Docetaxel anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Propylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-338-0

Edetate disodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	205-358-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children
Flammable liquids-Cat.2; H225 - Highly flammable liquid and vapor

Data Sources:	Publicly available toxicity information. Safety data sheets for individual ingredients.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 7 - Handling and Storage. Updated Section 2 - Hazard Identification.
Revision date:	01-Mar-2016 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

SAFETY DATA SHEET

Material Name: Docetaxel Injection
Revision date: 01-Mar-2016

Page 11 of 11
Version: 5.1
